Clinical Trials
71 trialsBevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences Ltd
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
GONGCHU Biotechnology Co., Ltd
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
CoRe_CC-3
German Cancer Research Center
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Shanghai PerHum Therapeutics Co., Ltd.
DUET-3
Xencor, Inc.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
A Study of PRT2527 in Participants With Advanced Solid Tumors
Prelude Therapeutics
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
Emory University
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Pfizer
A Study of PRT1419 in Patients With Advanced Solid Tumors
Prelude Therapeutics
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
GEN602
Genzada Pharmaceuticals USA, Inc.
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Ludwig Institute for Cancer Research
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
Philogen S.p.A.
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
SENECA
The University of Texas Health Science Center, Houston
A Safety Study of SGN-CD47M in Patients With Solid Tumors
Seagen Inc.
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer
National Institutes of Health Clinical Center (CC)
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
CytoMed Therapeutics Pte Ltd
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Virginia Commonwealth University
A Study Evaluating MM-310 in Patients With Solid Tumors
Merrimack Pharmaceuticals
EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
University Health Network, Toronto
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Corcept Therapeutics
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)